Back to Journals » Biologics: Targets and Therapy » Volume 13 » default

Biologics: Targets and Therapy


Archive: Volume 13, 2019

Has infliximab influenced the course and prognosis of acute severe ulcerative colitis?

Viscido A, Papi C, Latella G, Frieri G

Biologics: Targets and Therapy 2019, 13:23-31

Published Date: 9 April 2019

Efficacy of adalimumab as second-line therapy in a pediatric cohort of Crohn’s disease patients who failed infliximab therapy: the Italian Society of Pediatric Gastroenterology, Hepatology, and Nutrition experience

Alvisi P, Arrigo S, Cucchiara S, Lionetti P, Miele E, Romano C, Ravelli A, Knafelz D, Martelossi S, Guariso G, Accomando S, Zuin G, De Giacomo C, Balzani L, Gennari M, Aloi M

Biologics: Targets and Therapy 2019, 13:13-21

Published Date: 3 January 2019